MEDIA RELEASE

Landmark genetic study better predicts stomach cancer

New findings offer potential to develop more effective screening for stomach cancer, enabling timely and better early-stage treatments for patients

Singapore, [05 January 2018] – A research team led by National University Health System (NUHS) and Duke-NUS Medical School has used genomic technologies to better understand intestinal metaplasia (IM), a known risk factor for gastric (stomach) cancer. Patients with IM are six times more likely to develop stomach cancer than those without. This study is an important part of an ambitious investigation to understand why some people develop stomach cancer, while others do not. The research, which was published in one of the top cancer research journals, Cancer Cell, could also help detect patients who are infected with the Helicobacter pylori bacteria, which is also linked to the disease.

Stomach cancer is the third deadliest cancer in the world according to World Health Organization (WHO) statistics, and claims more than 300 lives yearly in Singapore. The disease is believed to be caused by infection with Helicobacter pylori but is potentially treatable if detected early. Unfortunately, more than two-thirds of stomach cancer patients are only diagnosed at an advanced stage.

“Previous genetic studies on IM have mainly focused on patients who were already diagnosed with stomach cancer but these are limited in their ability to predict who are likely to develop the disease and how the disease will progress,” said Professor Patrick Tan, co-lead investigator and Professor, Duke-NUS Medical School. Professor Tan is also Deputy Executive Director, Biomedical Research Council, Agency for Science, Technology, and Research, and a Senior Principal Investigator at the Cancer Science Institute of Singapore. “This new study is the first to comprehensively map out the genetic changes in IM in a cohort of stomach cancer-free subjects, which helps us better predict the possible occurrence and progression of the disease.”

Dr Yeoh Khay Guan, co-lead investigator and Deputy Chief Executive, NUHS as well as Dean, NUS Yong Loo Lin School of Medicine added, “Our study is the largest series of IM to be studied in detail by genetic analysis. These new findings help us understand why some people have a higher risk of progression to stomach cancer, and identify those who may benefit from closer follow-up to prevent cancer or to detect it early so that it can be cured.”

The researchers leveraged the near 3,000 participants-strong Gastric Cancer Epidemiology Programme (GCEP) cohort, recruited with the support of patients and doctors from four local public hospitals (National University Hospital, Tan Tock Seng Hospital, Singapore General Hospital, Changi General Hospital), to show that a comprehensive analysis of the genetic patterns of IM can predict its subsequent progression towards stomach cancer. The genetic analysis of IM helps to identify those with a higher risk of progression to stomach cancer, adding further information to what is available by microscopic examination alone.
The research team is using this new information to identify biomarkers that can be applied in future in the clinic to identify people who have a high risk of progression to stomach cancer.

The research was primarily supported by the National Research Foundation Singapore under its Translational and Clinical Research (TCR) Flagship Programme (TCR/009-NUHS/2013) which was administered by the Singapore Ministry of Health’s National Medical Research Council (NMRC), as well as by NMRC’s Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/0026/2015).

The GCEP project is the cardinal study of the Singapore Gastric Cancer Consortium (SGCC), which is a translational research group comprising clinicians and scientists from NUHS, Duke-NUS Medical School and other academic medical centres, universities, hospitals and research institutes working in stomach cancer research. The study aims to find more effective ways to treat stomach cancer and produce better patient outcomes, including targeted screening and early detection of the disease. Since its inception in 2007, SGCC has published more than 220 papers and filed 47 invention disclosures and patent applications, and has attracted more than S$23million in funding from 17 industry partners.

Reference
Huang, Kie Kyon et al.; “Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer”; Cancer Cell; https://doi.org/10.1016/j.ccell.2017.11.018


The new findings from the genomic studies could help better detect those at higher risk of stomach cancer much earlier, which is a crucial factor in treating the disease.

Image credit: Lee Jia Wei (NUS Yong Loo Lin School of Medicine) and Huang Kie Kyon (Duke-NUS Medical School)
For media queries, please contact:
Mr Eugene Low
Communications Office
National University Health System (NUHS)
Email: eugene_low@nuhs.edu.sg
Tel: (65) 6772 3991

Mr Indra Gurung
Communications
Duke-NUS Medical School
Email: indra.gurung@duke-nus.edu.sg
Tel: (65) 6516 4956

About the National University Health System (NUHS)

The National University Health System (NUHS) is an integrated Academic Health System and Regional Health System in Singapore that delivers value-driven, innovative and sustainable healthcare.

Institutions in the NUHS group include four hospitals - National University Hospital, Ng Teng Fong General Hospital, Jurong Community Hospital and Alexandra Hospital (in 2018); three National Specialty Centres - National University Cancer Institute, Singapore (NCIS), National University Heart Centre, Singapore (NUHCS) and National University Centre for Oral Health, Singapore (NUCOHS); a polyclinic group - the National University Polyclinics (NUP); one medical centre – Jurong Medical Centre; and three academic health sciences institutions – NUS Yong Loo Lin School of Medicine (including the Alice Lee Centre for Nursing Studies), NUS Faculty of Dentistry and NUS Saw Swee Hock School of Public Health.

With member institutions under a common governance structure, NUHS creates synergies for the advancement of health by integrating patient care, health science education and biomedical research.

As a Regional Health System, NUHS works closely with health and social care partners in the public, private and people sectors to develop and implement programmes that contribute to a healthy and engaged population in the Western part of Singapore.

For more information, please visit www.nuhs.edu.sg

About Duke-NUS Medical School

Duke-NUS Medical School (Duke-NUS, 杜克 — 新加坡国立大学医学院) was established in 2005 as a strategic collaboration between the Duke University School of Medicine, North Carolina, USA, and the National University of Singapore (NUS). Duke-NUS offers a graduate-entry, four-year MD (Doctor of Medicine) training programme, anchored on an innovative model of self-directed learning. The School
also offers MD/PhD and PhD programmes.

Duke-NUS has five Signature Research Programmes: Cancer and Stem Cell Biology, Neuroscience and Behavioural Disorders, Emerging Infectious Diseases, Cardiovascular and Metabolic Disorders, and Health Services and Systems Research.

The collaboration between Duke-NUS and Singapore Health Services (SingHealth) has established an Academic Medical Centre to advance our joint pursuits in clinical care, research and education to transform medicine and improve lives.

For more information, please visit www.duke-nus.edu.sg

**About Singapore Gastric Cancer Consortium***

The Singapore Gastric Cancer Consortium is an investigator–led national flagship research group comprising PI’s from academic medical centres, universities, hospitals and research institutes aiming to improve the outcomes of stomach cancer patients through studies focusing on early detection, improving treatment and advancing biologic understanding of gastric carcinogenesis. Key research projects include risk susceptibility studies, biomarker discovery and validation, the genetic mapping of stomach cancer and clinical trials of novel treatment agents. Led by Lead Principal Investigator Associate Professor Yeoh Khay Guan, the consortium was awarded the first Translational and Clinical Research (TCR) Flagship Research Grant by the National Research Foundation Singapore in 2007. A five-year renewal was subsequently awarded to the consortium for 2013-2018.

*National University Health System, National University of Singapore, Yong Loo Lin School of Medicine, Cancer Science Institute of Singapore, Duke-NUS Medical School, Nanyang Technological University, National University Hospital, Singapore General Hospital, Tan Tock Seng Hospital, Changi General Hospital, National Cancer Centre Singapore, Experimental Therapeutics Centre, Genome Institute of Singapore, Institute of Medical Biology, Singapore Immunology Network, Bioprocessing Technology Institute.*